Cargando…

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

OBJECTIVES: SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). In a randomised, double-blind, 52-week study, SB4 demonstrated comparable efficacy and safety to ETN in patients with rheumatoid arthritis (RA). The open-label extension period evaluated long-term efficacy, safety and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Stasiuk, Barbara, Hilt, Joanna, Mosterova, Zdenka, Cheong, Soo Yeon, Ghil, Jeehoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705842/ https://www.ncbi.nlm.nih.gov/pubmed/28794078 http://dx.doi.org/10.1136/annrheumdis-2017-211591

Ejemplares similares

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
por: Emery, Paul, et al.
Publicado: (2017)

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
por: Smolen, Josef S, et al.
Publicado: (2018)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
por: Goncalves, Joao, et al.
Publicado: (2019)

Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease
por: Benucci, Maurizio, et al.
Publicado: (2022)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study
por: Parisi, Simone, et al.
Publicado: (2022)

Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT Study
por: Luciano, Nicoletta, et al.
Publicado: (2022)

On the decay of 110Sb, 111Sb, 112Sb, 113Sb and 114Sb
por: Sunier, J W, et al.
Publicado: (1970)

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases
por: Bruni, Cosimo, et al.
Publicado: (2020)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
por: Choe, Jung-Yoon, et al.
Publicado: (2017)

Between Elemental Match and Mismatch: From K(12)Ge(3.5)Sb(6) to Salts of (Ge(2)Sb(2))(2−), (Ge(4)Sb(12))(4−), and (Ge(4)Sb(14))(4−)
por: Beuthert, Katrin, et al.
Publicado: (2022)

Phase Equilibria and Crystal Growth in the Alkali Antimonate Systems Sb(2)O(4)–NaSbO(3/) Sb(2)O(4)–KSbO(3/), and Sb(2)O(4)–NaSbO(3)–NaF
por: Waring, J. L., et al.
Publicado: (1976)

Two sb or not two sb?
por: Kado, M, et al.
Publicado: (2000)

A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
por: Lee, Yoon Jung, et al.
Publicado: (2016)

Correction: Benucci et al. Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. J. Pers. Med. 2022, 12, 1174
por: Benucci, Maurizio, et al.
Publicado: (2023)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
por: Yoo, Wan-Hee, et al.
Publicado: (2022)

Switching patients with inflammatory arthritis from Etanercept (Enbrel(®)) to the biosimilar drug, SB4 (Benepali(®)): A single-centre retrospective observational study in the UK and a review of the literature
por: Madenidou, Anastasia-Vasiliki, et al.
Publicado: (2019)

A Single Amino Acid Substitution Makes WNK4 Susceptible to SB 203580 and SB 202190
por: Glover, Mark, et al.
Publicado: (2010)

Rb(2)Sb(4)O(11)
por: Kalpana, Govindaraasan, et al.
Publicado: (2009)

Ba(2)Sb(4)GeS(10)
por: Geng, Lei
Publicado: (2013)

Synthesis and Electronic Structure of Mid-Infrared Absorbing Cu(3)SbSe(4) and Cu(x)SbSe(4) Nanocrystals
por: Moser, Annina, et al.
Publicado: (2023)

Sorghum Phytochrome B Inhibits Flowering in Long Days by Activating Expression of SbPRR37 and SbGHD7, Repressors of SbEHD1, SbCN8 and SbCN12
por: Yang, Shanshan, et al.
Publicado: (2014)

Smooth termination of intruder bands in $^{109}$Sb and $^{51}$Sb
por: Schnare, H, et al.
Publicado: (1996)

Synthesis and Crystal Structure of the Zintl Phases NaSrSb, NaBaSb and NaEuSb
por: Wang, Yi, et al.
Publicado: (2023)

Crystal structure of Ba(5)In(4)Sb(6)
por: Pan, Ming-Yan, et al.
Publicado: (2015)

Modeling of switching mechanism in GeSbTe chalcogenide superlattices
por: Yu, Xiaoming, et al.
Publicado: (2015)

Metals in medicine project: Investigation of the treatment of Leishmaniases with antimony containing drug compounds using perturbed angular correlation spectroscopy with parent Isotopes $^{116}$Sb, $^{118}$Sb, $^{120}$Sb, ($^{128}$Sb), $^{130}$Sb
por: Shaapan, R M, et al.
Publicado: (2012)

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
por: van Vollenhoven, Ronald F, et al.
Publicado: (2016)

Metal-Semiconductor AsSb-Al(0.6)Ga(0.4)As(0.97)Sb(0.03) Metamaterial
por: Bert, Nikolay, et al.
Publicado: (2022)

The effect of Mn(2)Sb(2) and Mn(2)Sb secondary phases on magnetism in (GaMn)Sb thin films
por: Calderón, Jorge A., et al.
Publicado: (2020)

The ESSnuSB Accumulator
por: Wildner, Elena
Publicado: (2018)

Site and Buildings (SB)
Publicado: (1964)

Site and Buildings (SB)
Publicado: (1965)

Scintillation Characteristics of Sb-doped $PbWO_{4}$ crystals
por: Chen, H F, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_pal9mdbhi1qq54ch52b6abv7tf